Home›Stock Screener›Shukra Pharmaceuticals›Financial Statements

Shukra Pharmaceuticals Financial Statements

3 Years of Data
2026 - 2024

Shukra Pharmaceuticals financial statements. In FY2026, Shukra Pharmaceuticals (SHUKRAPHAR) reported revenue ₹45 Cr, net profit ₹13 Cr and EPS ₹0.29, with a net profit margin of 28.9% and ROE of 14.4%. Full financial statements from FY2024 to FY2026 (3 years) — income statement, balance sheet and cash flow in ₹ Crores. Download as Excel or CSV. Explore Shukra Pharmaceuticals intrinsic worth to estimate fundamental worth using multiple valuation models.

Complete Financial Data Export

Profitability Ratios

Net Profit Margin 28.89% 2026 data
EBITDA Margin 42.22% 2026 data
Operating Margin 42.00% 2026 data
Return on Assets 11.11% 2026 data
Return on Equity 14.44% 2026 data

Balance Sheet Ratios

Equity Ratio 76.92% 2026 data
Asset Turnover 0.38 2026 data

SHUKRAPHAR Revenue, Net Profit & EBITDA — Year-on-Year Growth

SHUKRAPHAR YoY (Sept 2025 vs Sept 2026) — revenue +462.5%, net profit +550.0%, EBITDA +1800.0%, expenses +333.3%. See SHUKRAPHAR price to book ratio to compare market price against book value per share.

Revenue Growth
+462.5%
Year-over-Year
Net Profit Growth
+550.0%
Year-over-Year
EBITDA Growth
+1800.0%
Year-over-Year
Expense Growth
+333.3%
Year-over-Year
Assets Growth
+34.5%
Year-over-Year
Equity Growth
+42.9%
Year-over-Year
Operating Cash Flow Growth
-62.5%
Year-over-Year
Investing Cash Flow Growth
-1300.0%
Year-over-Year
Financing Cash Flow Growth
+200.0%
Year-over-Year

SHUKRAPHAR Income Statement — Revenue, EBITDA & Net Profit

Shukra Pharmaceuticals revenue ₹45 Cr, EBITDA ₹19 Cr, net profit ₹13 Cr, EPS ₹0.29 (2026) — net profit margin 28.9%. For live price, earnings ratios and company overview, see Shukra Pharmaceuticals share price today.

Periods ₹ Crores
Particulars Sept 2026 Mar 2026 Jun 2026 Sept 2025 Mar 2025 Jun 2025 Dec 2025 Dec 2024
Revenue 45 7 24 8 15 7 40 12
Expenses 26 6 4 6 6 4 12 7
EBITDA 19 2 20 1 9 2 28 5
Operating Profit Margin % 42.00% 11.00% 81.00% -7.00% 55.00% 24.00% 69.00% 37.00%
Depreciation 1 1 1 1 1 1 1 1
Interest 0 0 0 0 0 0 0 0
Profit Before Tax 18 0 18 0 8 1 27 4
Tax 5 2 5 -2 2 0 7 1
Net Profit 13 -2 13 2 5 1 20 3
Earnings Per Share (₹) 0.29 -0.04 0.30 0.05 0.12 0.02 0.47 0.72

SHUKRAPHAR Balance Sheet — Assets, Liabilities & Shareholders' Equity

SHUKRAPHAR total assets ₹117 Cr, total equity ₹90 Cr, total liabilities ₹ Cr (2026) — ROE 14.4%.

Years Annual Data ₹ Crores
Particulars 2026 2025
ASSETS
Total Assets 117 87
Current Assets
Fixed Assets 22 19
Capital Work in Progress 12 2
Investments 0 0
Other Assets 84 65
LIABILITIES
Total Liabilities
Current Liabilities 5 7
Non-Current Liabilities
SHAREHOLDERS' EQUITY
Total Equity 90 63
Share Capital 44 44
Reserves & Surplus 41 19

SHUKRAPHAR Cash Flow Statement — Operating, Investing & Financing

Shukra Pharmaceuticals operating cash flow ₹3 Cr, investing ₹-14 Cr, financing ₹5 Cr, net cash flow ₹-6 Cr (2026).

Periods ₹ Crores
Particulars March 2026 March 2025
Operating Activities 3 8
Investing Activities -14 -1
Financing Activities 5 -5
Net Cash Flow -6 2